Navigation Links
Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
Date:12/6/2008

act will break at that time.

Results from this multinational phase III study demonstrate that the combination of fludarabine, cyclophosphamide, and rituximab (FCR) provides a 10-month improvement in progression-free survival and a near doubling of complete response rates in patients with relapsed or refractory chronic lymphocytic leukemia.

A total of 552 patients from 17 countries with relapsed or refractory chronic lymphocytic leukemia were randomized to receive six 28-day cycles of fludarabine (25 mg/m^2 intravenously on days 1 to 3) and cyclophosphamide (250 mg/m^2 intravenously on days 1 to 3) alone (FC) or in combination with rituximab (FCR) (375 mg/m^2 rituximab intravenously at the start of first cycle and 500 mg/m^2 on day 1 for all subsequent cycles). Patients previously had received an average of one previous treatment regimen, including a single-agent alkylator therapy (66 percent), a purine-analog therapy (16 percent), or combination chemotherapy treatments (18 percent). The primary endpoint of the study was progression- free survival.

Patients in the FCR arm achieved a 30.6-month progression-free survival compared with 20.6 months in the FC arm, translating into a significant 10-month increase in progression-free survival for FCR combination therapy. The overall response rate was significantly higher in the FCR arm (70 percent) as compared with the FC arm (58 percent), because of superior complete-response rates in the FCR arm (24 percent versus 13 percent, respectively). While median overall survival in the FC arm was reached at 53 months, it had not yet been reached in the FCR arm.

While Grade 3 and 4 adverse events were more prevalent in the FCR arm (80 percent) as compared with the FC arm (74 percent), serious adverse events were similar in each treatment arm (50 percent versus 48 percent, respectively). Overall, the FCR combination showed a favorable risk-benefit pr
'/>"/>

SOURCE American Society of Hematology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. University of Kansas Medical Center to Deploy Velos eResearch System-Wide
5. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
6. Dominos Pizza Pledges Support to the Fifth Annual St. Jude Childrens Research Hospital(R) Thanks and Giving(R) Campaign
7. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
8. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
9. Sarah Cannon Research Institute Selects OmniComm Systems Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management
10. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
11. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  Uroplasty, Inc. (NASDAQ: ... manufactures and markets innovative proprietary products to treat ... fiscal 2015 first quarter ended June 30, 2014.  ...  PC Neuromodulation System grew 19% to $4.1 million, ... quarter of the prior year.  Total revenue for ...
(Date:7/24/2014)... OAKS, Calif. , July 24, 2014 Amgen ... report its second quarter financial results on Tuesday, July 29, ... announcement will be followed by a conference call with the ... from Amgen will be Robert A. Bradway , chairman ... management team. Live audio of the conference call ...
(Date:7/24/2014)... VANCOUVER, British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today ... the company,s fiscal year from December 31 to June 30. ... before September 30, 2014. Jeffrey Bacha , ... year end is an important step in achieving our goal ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3
... July 14 Samsung Medical Center and the world,s leading bio-pharmaceutical company ... research partnership to jointly analyze tumors from Korean patients to generate gene expression ... patients with liver cancer. , , ... http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ) , , , ...
... , SANTA ROSA, Calif. , July 14 ... Santa Rosa, California , today received a notice of ... company which was started in 2006 has thirteen additional patent ... the world for related spinal therapies and devices. The lead ...
Cached Medicine Technology:Pfizer and SMC Collaborate on Liver Cancer 2Pfizer and SMC Collaborate on Liver Cancer 3Osseon Receives Patent Allowance for Novel Spinal VCF Treatment Devices 2
(Date:7/25/2014)... Merrill Corporation ( http://www.merrillcorp.com ), ... the financial, legal, healthcare and other corporate markets, ... Merrill DataSite, has been recognized as the “Technology ... the M&A Awards 2014 event. , ... management teams, advisors and financiers as they demonstrate ...
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 AttorneyOne.com, a ... the latest information from the FDA on Ibuprofen and ... 21, that one lot of Ibuprofen and one lot of ... due to mislabeled packaging. Oxcarbazepine is used for the ... , The reason for the recall is that ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Art of Facial ... services to those in Toronto who are looking for minor ... study done by the American Academy of Facial Plastic ... 2014, interest in facial plastic surgery showed a surprising increase ... rose 10 percent, while hair transplants increased by 7 percent ...
(Date:7/25/2014)... North York, ON (PRWEB) July 25, 2014 A ... St. Michael’s Hospital revealed that 39 percent of all children ... see a dentist. , The survey looked at 2,505 children during ... were all around four years of age. The final result ... had any dental care. Many of these children were from lower-income ...
(Date:7/25/2014)... Ticket Down is a reliable source for cheap ... California Memorial Stadium. With the post-World Cup emotions still rolling ... the 2014 Guinness International Champions Cup have brought eight of ... representing La Liga, English Premier League, Serie A, and Superleague ... players from around the world to 12 American cities and ...
Breaking Medicine News(10 mins):Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 3Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3
... experts at NewYork-Presbyterian Hospital/Columbia University Medical Center are presenting ... of Reproductive Medicine (ASRM) meeting in San Francisco, Nov. ... Mark V. Sauer is chairing the invited symposia, "Management ... speak on "Clinical Paradigms Gained From 10 Years of ...
... Gamble Company,(NYSE: PG ) today announced that the ... confirmed the validity of P&G,s patent for a consumer-,preferred ... of P&G,s Folgers coffee brand., In August of ... House plastic container infringes P&G,s patent. In October of ...
... be done in-house, HARRISBURG, Pa., Nov. 7 ... across Pennsylvania,in the County Assistance Offices, described Governor ... the Department of Public Welfare,s,database for Medicaid recipients ... "The amount of money this administration has agreed ...
... LYNBROOK, N.Y., Nov. 7 BioSpecifics,Technologies Corp. (OTC ... class collagenase-based products, today,announced that BioSpecifics, President, Tom ... Rodman & Renshaw 10th Annual Healthcare,Conference on Wednesday, ... New York,Palace Hotel in New York, NY., ...
... Program for People Living with Diabetes ... Returns to San Diego, ... and health fair will be held November 22 from,8:30 a.m. to 5:00 ... in diabetes care to people with all,types of diabetes, those at risk ...
... better results, including survival rates , , FRIDAY, Nov. 7 ... best choice for adults requiring surgery to repair a ... congenital heart defect occurs when there,s abnormal pre-birth development ... , The researchers analyzed a national database to identify ...
Cached Medicine News:Health News:Fertility experts present the latest research at reproductive medicine meeting 2Health News:Fertility experts present the latest research at reproductive medicine meeting 3Health News:U.S. Patent Office Upholds P&G Coffee Patent 2Health News:Service Employees Outraged Over Rendell Spending 2Health News:Centennial Taking Control of Your Diabetes Conference Returns to San Diego to Bring Answers, Advocacy and Hope 2Health News:Pediatric Heart Surgeons May Be Best Choice for Adults 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: